Zhang Jun-Jie, Gao Xiao-Fei, Han Ya-Ling, Kan Jing, Tao Ling, Ge Zhen, Tresukosol Damras, Lu Shu, Ma Li-Kun, Li Feng, Yang Song, Zhang Jun, Munawar Muhammad, Li Li, Zhang Rui-Yan, Zeng He-Song, Santoso Teguh, Xie Ping, Jin Ze-Ning, Han Leng, Yin Wei-Hsian, Qian Xue-Song, Li Qi-Hua, Hong Lang, Paiboon Chotnoparatpat, Wang Yan, Liu Li-Jun, Zhou Lei, Wu Xue-Ming, Wen Shang-Yu, Lu Qing-Hua, Yuan Jun-Qiang, Chen Liang-Long, Lavarra Francesco, Rodríguez Alfredo E, Zhou Li-Min, Ding Shi-Qin, Vichairuangthum Kitigon, Zhu Yuan-Sheng, Yu Meng-Yue, Chen Chan, Sheiban Imad, Xia Yong, Tian Yu-Long, Shang Zheng-Lu, Jiang Qing, Zhen Yong-Hong, Wang Xin, Ye Fei, Tian Nai-Liang, Lin Song, Liu Zhi-Zhong, Chen Shao-Liang
Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nangjing, Jiangsu, China.
Department of Cardiology, The General Hospital of Shenyang Military, Shenyang, China.
BMJ Open. 2018 Mar 6;8(3):e020019. doi: 10.1136/bmjopen-2017-020019.
Provisional stenting (PS) for simple coronary bifurcation lesions is the mainstay of treatment. A systematic two-stent approach is widely used for complex bifurcation lesions (CBLs). However, a randomised comparison of PS and two-stent techniques for CBLs has never been studied. Accordingly, the present study is designed to elucidate the benefits of two-stent treatment over PS in patients with CBLs.
This DEFINITION II study is a prospective, multinational, randomised, endpoint-driven trial to compare the benefits of the two-stent technique with PS for CBLs. A total of 660 patients with CBLs will be randomised in a 1:1 fashion to receive either PS or the two-stent technique. The primary endpoint is the rate of 12-month target lesion failure defined as the composite of cardiac death, target vessel myocardial infarction (MI) and clinically driven target lesion revascularisation. The major secondary endpoints include all causes of death, MI, target vessel revascularisation, in-stent restenosis, stroke and each individual component of the primary endpoints. The safety endpoint is the occurrence of definite or probable stent thrombosis.
The study protocol and informed consent have been approved by the Institutional Review Board of Nanjing First Hospital, and accepted by each participating centre. Written informed consent was obtained from all enrolled patients. Findings of the study will be published in a peer-reviewed journal and disseminated at conferences.
NCT02284750; Pre-results.
对于简单冠状动脉分叉病变,临时支架置入术(PS)是主要的治疗方法。系统性双支架置入法广泛应用于复杂分叉病变(CBL)。然而,从未对CBL的PS和双支架技术进行过随机对照研究。因此,本研究旨在阐明双支架治疗相对于PS在CBL患者中的益处。
这项DEFINITION II研究是一项前瞻性、多中心、随机、终点驱动的试验,旨在比较双支架技术与PS治疗CBL的益处。总共660例CBL患者将以1:1的比例随机分组,接受PS或双支架技术治疗。主要终点是12个月时的靶病变失败率,定义为心源性死亡、靶血管心肌梗死(MI)和临床驱动的靶病变血运重建的复合终点。主要次要终点包括全因死亡、MI、靶血管血运重建、支架内再狭窄、卒中以及主要终点的各个单独组成部分。安全终点是明确或可能的支架血栓形成的发生情况。
研究方案和知情同意书已获南京第一医院机构审查委员会批准,并被各参与中心接受。所有入组患者均获得了书面知情同意书。研究结果将发表在同行评审期刊上,并在会议上公布。
NCT02284750;预结果。